Icelandair: Traffic Data January 2023
In January 2023, Icelandair’s passengers were 210 thousand, compared to 113 thousand in January last year. Capacity in January was 93% of January 2020 levels, the last normal operating January before the pandemic, and 79% of 2019 levels.
Passengers on international flights were 191 thousand, compared to 102 thousand in January 2022, an increase of 88%. Passengers to Iceland were 75 thousand and from Iceland 47 thousand. Via passengers were around 69 thousand. On-time performance on international flights was 75%. On time performance and passenger numbers were affected by weather related disruptions in January. The load factor on international flights improved significantly from 59.5% in January 2022 to 74.6% in January this year.
Passengers on domestic flights were 18,500, compared to around 12 thousand in January 2022. On time performance was 84%. Load factor on domestic flights was 72.4%. Weather in Iceland caused disruption in the domestic network in January, affecting on time performance and passenger numbers.
Sold block hours in charter flights decreased by 3%. Freight measured in Freight Ton Kilometers increased by 31% compared to January last year. The increase in cargo is due to increased capacity with the introduction of a Boeing 767 widebody into the cargo fleet.
Route Network | Jan 23 | Jan 22 | CHG (%) |
Number of Passengers | 209,981 | 113,403 | 85% |
Load Factor | 74.6% | 59.6% | 15.0 ppt |
Available Seat KM (ASK´000,000) | 797.5 | 534.1 | 49% |
Revenue Passenger KM (RPK´000,000) | 594.7 | 318.3 | 87% |
INTERNATIONAL FLIGHTS | Jan 23 | Jan 22 | CHG (%) |
To market (passengers) | 74,691 | 45,322 | 65% |
From market (passengers) | 47,493 | 24,751 | 92% |
Via market (passengers) | 69,277 | 31,608 | 119% |
Number of Passengers | 191,461 | 101,681 | 88% |
Load Factor | 74.6% | 59.5% | 15.1 ppt |
Available Seat KM (ASK´000,000) | 790.1 | 529.5 | 49% |
Revenue Passenger KM (RPK´000,000) | 589.3 | 314.9 | 87% |
Stage length (KM) | 3,000 | 3,082 | -3% |
On-Time-Performance (Arrivals) | 75.0% | 73.0% | 2.0 ppt |
DOMESTIC FLIGHTS | Jan 23 | Jan 22 | CHG (%) |
Number of Passengers | 18,520 | 11,722 | 58% |
Load Factor | 72.4% | 72.9% | -0.5 ppt |
Available Seat KM (ASK´000,000) | 7.4 | 4.7 | 60% |
On-Time-Performance (Arrivals) | 84% | 65% | 19.0 ppt |
Cargo & Leasing | Jan 23 | Jan 22 | CHG (%) |
Sold Block Hours - Leasing | 1,051 | 1,083 | -3% |
Freight Tonne KM (FTK´000) | 13,834 | 10,600 | 31% |
CO2 EMISSIONS | Jan 23 | Jan 22 | CHG (%) |
Total CO2 emissions tonnes | 57,850 | 41,470 | 39% |
CO2 emissions per OTK | 0.83 | 1.07 | -23% |
Contact information
Investors: Iris Hulda Thorisdottir, Director Investor Relations. E-mail: iris@icelandair.is
Media: Asdis Petursdottir, Director Communications. E-mail: asdis@icelandair.is
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates24.4.2024 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in kidney function observed with varoglutamstat 600mg BID in VIVIAD over two years based on pre-specified analysis of the estimated glomerular filtration rateCompany plans to explore potential of varoglutamstat in kidney disease in a shift of strategic focus towards inflammatory and fibrotic disorders VIVA-MIND Phase 2 study to be discontinued early, in H2 2024, which will enable accelerated data analysis and inform varoglutamstat development strategyCompany is taking steps to reduce cash utilizatio
Wereldhave Trading update Q1 202424.4.2024 07:00:00 CEST | Press release
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 2024 Kern annual development awardForecast FY 2024 DRPS € 1.75 reiterated Attachment Trading update Q1 2024 Wereldhave N.V.
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma24.4.2024 07:00:00 CEST | Press release
ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023. ‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ c